ABSTRACT

Eleven ruthenium complexes of the type Ru(L)2(Lı)]2+ have been prepared by reacting Ru(L)2C12 (where L=2,2’-bipyridine (bpy)/ 1.10-phcnanthrolinc (phenyl)/ dimethylsulfoxide (DMSO)) with ligands L,= HBT, FCl-HBT, IINH, NCb-MPC, OCH3-MPC, N(CH3’)2-MPC, Cl-MPC (where HBT=2-hydrazinyl-1,3-benzothiazole, FCl-HBT =5-chloro-6-fhıoro-2-hydrazinyl-l,3-benzothiazole, IINH=N-2-oxo-l,2-dihydro-3H-indol-3-ylidene]pyridine-4-carbo-hydrazide, N02-MPC=N(4-nitrophenyl)-methylidene-pyridine-4-carbohydrazide,OCH3-MPC=N(4-methoxyphenyl)methylidene-pyridine-4-carbohydrazide, N(CH3)2-MPC=N(4-dimethylaminophenyl)methylidene-pyridine-4-carbo-hydrazide, C1-MPC=N(4-clılorophenyl)methylidene-pyridine-4-carbohydrazide. The title complexes were subjected to in vitro cytostatic activity testing against the huınan cervix carcinoma HeLa and T-lymphocyte CEM celi lines, and the murine leukemia tumor celi line L1210. The most active ruthenium complex TKA-9 [Ru(phen)2(N(CH3)2-MPC)] revealed a cytostatic activity of 16 pM against CEM, 20 pM against L1210 and 5.5 pM against HeLa tumor cells. Ali complexes were also tested for antiviral activity against a wide variety of DNA and RNA vimses, but found not to display selective activity at subtoxic concentrations.